EW vs. MDLN: Edwards Lifesciences vs. Medline Stock Comparison

Company Profile

Edwards Lifesciences (EW) and Medline (MDLN) both belong to the Health Care Equipment & Supplies industry, though EW is classified under Health Care Equipment while MDLN falls under Health Care Supplies.

Edwards Lifesciences (EW) has been public since March 27, 2000, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Edwards Lifesciences (EW) has a non-negative beta of 0.78.

Risk-Adjusted Performance

Risk-Return Positioning

Both EW and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Edwards Lifesciences (EW) at 9.33% and Medline (MDLN) at 4.85% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Edwards Lifesciences (EW) at 15.30% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

Edwards Lifesciences (EW) at 30.15% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Edwards Lifesciences (EW) reports revenue growth of 11.55%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% delivers above-range EPS growth, while Edwards Lifesciences (EW) at -73.74% falls into the bottom quartile — a wide split in earnings momentum.

Growth Metrics

Financial Strength

Both Edwards Lifesciences (EW) at 4.60 and Medline (MDLN) at 4.04 post current ratio above their industries’ typical mid-ranges — short-term liquidity appears comfortable, though unusually high readings can point to idle current assets.

Edwards Lifesciences (EW) at 0.06 keeps leverage in the lower industry quartile, while Medline (MDLN) at 0.65 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Edwards Lifesciences (EW) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Edwards Lifesciences (EW) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Edwards Lifesciences (EW) at 59.38 sits in the richer P/E ratio quartile, and Medline (MDLN) at 90.09 is richer still, above its industry range.

Medline (MDLN) at 1.70 is priced about in line with its industry on P/S ratio, while Edwards Lifesciences (EW) at 8.80 sits in the pricier quartile — EW costs more per dollar of sales.

On P/B ratio, both Edwards Lifesciences (EW) at 5.41 and Medline (MDLN) at 2.95 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics